<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Foglierini, Mathilde</dc:creator>
  <dc:creator>Marcandalli, Jessica</dc:creator>
  <dc:creator>Perez, Laurent</dc:creator>
  <dc:date>2019-05-15</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Human cytomegalovirus (HCMV) is the leading viral cause of congenital birth defects and  is responsible for morbidity and mortality in immunosuppressed individuals. Considerable  efforts have been deployed over the last decade to develop a vaccine capable of  preventing HCMV infection. However, in recent clinical trials, vaccines showed at best  modest efficacy in preventing infection. These findings might be explained by the high  level of sequence polymorphism at the genomic level. To investigate if genomic variation  also leads to antigenic variation, we performed a bioinformatic sequence analysis and  evaluated the percentage of conservation at the amino acid level of all the proteins present  in the virion envelope. Using more than two hundred sequences per envelope glycoprotein  and analyzing their degree of conservation, we observe that antigenic variation is in large  part limited to three proteins. In addition, we demonstrate that the two leading vaccine  candidates, the pentamer and gB complexes, are well conserved at the amino acid level.  These results suggest that despite genomic polymorphism, antigenic variability is not  involved in the modest efficacy observed in the recent clinical trials for a HCMV vaccine.  We therefore propose that next-generation vaccines should focus on stabilizing and  refining the gB domains needed to induce a protective humoral response.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/319128</dc:identifier>
  <dc:identifier>https://n2t.net/ark:/12658/srd1319128</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319128/files/Foglierini_FrontMicrobiol_2019.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3389/fmicb.2019.01005</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319128</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Frontiers in microbiology. - 2019, vol. 10, p. 1005</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Human cytomegalovirus</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Envelope glycoproteins</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Viral diversity</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Multiple sequence alignment</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Protein sequence analysis</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Phylogenic analysis</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/616</dc:subject>
  <dc:title xmlns:ns7="xml" ns7:lang="en">HCMV envelope glycoprotein diversity demystified</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
